



Register Now

**u<sup>b</sup> UNIVERSITÄT  
BERN**



# International Medical Cannabis Conference University of Bern 2025 IMCCB-25

Thursday, February 13<sup>th</sup> to Friday, February 14<sup>th</sup>, 2025  
at Von Roll Campus, Bern, Switzerland



**u<sup>b</sup> UNIVERSITÄT  
BERN**



**SGCM-SSCM**  
Swiss Society  
of Cannabis in Medicine

**Karger**



SAPHS  
Swiss Academy  
of Pharmaceutical  
Sciences  
[www.saphs.ch](http://www.saphs.ch)

**DMCG**

Deutsche Medizinal-  
Cannabis Gesellschaft e.V.

 Swiss Confederation  
Federal Department  
of Home Affairs FDHA  
Federal Office  
of Public Health FOPH

<https://www.ibmm.unibe.ch/imccb25>

❖ **Organizers, conference chairs:**

Jürg Gertsch  
Institute of Biochemistry and Molecular Medicine, University of Bern  
Rudolf Brenneisen  
Swiss Academy of Pharmaceutical Sciences, SAPHW

❖ **Scientific board:**

Kristina Adorjan, University of Bern, Switzerland  
Federica Bianchi, FAHPA & HUG, Switzerland  
Thomas Herdegen, Christian-Albrechts-Universität Kiel, Germany  
Undine Lang, University of Basel, Switzerland  
Paola Luciani, University of Bern, Switzerland  
Simon Nicolussi, SGCM-SSCM, Switzerland  
Joseph Tam, Hebrew University, Israel  
Claude Vaney, Switzerland

❖ **Invitation to the IMCCB-25:**

Dear colleagues from academia, clinics, and industry,

We are delighted to invite you to participate in the upcoming International Medical Cannabis Conference Bern (**IMCCB-25**), scheduled for February 13-14, 2025, at the University of Bern in Switzerland. Building on the success of previous Swiss cannabis conferences, **IMCCB-25** aspires to bring together a diverse assembly of leading researchers, clinicians, industry professionals, and other experts and opinion leaders from around the world. The conference will cover a broad spectrum of topics, including basic and clinical methodologies, safety, analytics, pharmaceuticals, regulatory and legal considerations, pharmacological insights, and technological advancements.

Our emphasis is on practical implications for patients, researchers, medical persons, and industry leaders alike. Additional topics include palliative care, women medicine, pediatric, psychiatric and geriatric diseases, niche indications, as well as non-medical cannabis use. The **IMCCB-25** seeks to inform participants about the latest evidence and concepts regarding cannabis- and cannabinoid-based therapies. It aims to assist prescribers in practically implementing best practices based on current research, expert opinions and therapy guidelines. Furthermore, the conference provides a unique platform for the exchange of ideas and practices in medical cannabis among professionals and patients, fostering innovative and engaging discussions.

By attending IMCCB-25, you will become part of fascinating and lively debates that contribute to the collective knowledge in this expanding and challenging field. We eagerly look forward to welcoming you to the vibrant and wonderful city of Bern for this enriching and collaborative experience.

Sincerely,  
Jürg Gertsch & Rudolf Brenneisen  
Conference chairs

## ❖ Scientific program:

### ➤ 9 Sessions, 32 lectures, 5 panels – Ask the Experts

#### ➤ Lecture topics:

- The Day Anandamide Almost Died and Other Endocannabinoid Stories
- The Endocannabinoidome: From Cannabis to the Gut Microbiome
- Cannabinoid and Stress – Mechanistic Aspects
- 50 Years of Phytochemistry and Analytics
- Personalized Cannabis Medicines – What is the Evidence?
- Sites and Mechanisms Underlying Cannabinoid-Induced Antinociception
- CBMs in Pain Disorders – What is the Evidence?
- Cannabinoids for Neurodegeneration - Fact or Fiction?
- CBMs in Psychiatric and Substance Use Disorders
- Cannabinoid-based Therapies for Treating Metabolic Diseases
- The Value of Real-World Evidence in Cannabis Therapies
- The Use of Tetrahydrocannabinol in Palliative Cancer Patients
- CBMs in Sleep Disorders
- CBMs in Geriatrics and Palliative Care
- Risks of Cannabis-based Medicine
- Cannabinoid Drug Interaction Digital Tool
- Challenges in Production of CBMs
- Pilot Study on Cannabis E-Cigarettes
- Digital Healthcare Solutions Supporting Cannabinoid Therapy
- Reporting System MeCanna – Features, Challenges and Opportunities
- What is Clinical Evidence?
- Non-medical Cannabis Use: First Results from a Swiss Pilot Trial (Cann-L)
- Hot Topics in Cannabis Research
- Country Reports: Latin America, USA, Germany, Spain
- Short oral communications

#### ➤ Poster session

## ❖ Speakers:

Daniele Piomelli, University of California, Irvine, USA

Vincenzo Di Marzo, Université Laval, Canada

Beat Lutz, University Medical Center Mainz, Germany

Mahmoud ElSohly, University of Mississippi, Oxford, USA

Guillermo Moreno-Sanz, Khiron Europe, Spain

David P. Finn, University of Galway, Ireland

Matthias Karst, Hannover Medical School, Hannover, Germany

Markus Weber, Cantonal Hospital St. Gallen, Switzerland

Patrik Roser, University Hospital of Psychiatry Zurich, Switzerland

Yossi Tam, The Hebrew University of Jerusalem, Israel

Anne Katrin Schlag, Drug Science & Imperial College London, UK

Thomas Herdegen, University Clinics of Kiel, Germany

Kirsten Müller-Vahl, Medizinische Hochschule Hannover, Germany

Federica Bianchi, Geneva University Hospital, Switzerland

## ❖ Speakers (cont.):

Margaret Haney, Columbia University Medical Center, New York, USA

Kent E. Vrana, Penn State College of Medicine, Hershey, USA

Thomas R. Tölle, The Entrepreneurial University TUM, Germany

Reto Auer, University of Bern, Switzerland

Almut Winterstein, University of Florida, Gainesville, USA

Garvin Hirt, Copeia GmbH, Bergisch Gladbach, Germany

John Ioannidis, Stanford University, USA

Frank Zobel, Addiction Switzerland, Lausanne, Switzerland

Jürg Gertsch, University of Bern, Switzerland

Sandra Carillo, University of Panama, Colombia

Amie Goodin, University of Florida, Gainesville, USA

Konrad F. Cimander, Wedemark, Germany

Christian Werz, Federal Office of Public Health, Switzerland

## ❖ Call for abstracts:

Poster presentations and short oral communications are subject to peer-reviewed accepted abstracts.

- For submission guidelines, formatting, templates, and deadlines see IMCCB-25 website <https://www.imccb.org>.
- All lecture and poster abstracts will be published in *Medical Cannabis and Cannabinoids* (Karger Publishers, Basel), which is the official open-access conference journal.

## ❖ Sponsoring and exhibition:

- The IMCCB-25 is a non-profit academic event at the University of Bern. However, it can only be realized through financial support of industry, authorities, professional societies and academies, patient organizations, and science foundations.
- Sponsoring packages: see IMCCB-25 website.
- The exhibition area is located in the meeting and poster forum at the main

## ❖ Registration and fees:

- Registration: via ConfTool, see IMCCB-25 website ([www.imccb.org](http://www.imccb.org))

- Fees:

Industry members	CHF	555
Professionals, others	CHF	310
Students	CHF	110
1-Day ticket	CHF	220
Online participation	CHF	220

❖ **Accommodation and general information about the city of Bern:**

The beautiful city of Bern offers a range of hotels and accommodations. Please book early and refer to: <https://www.bern.com/en/home>. We will organize few tours and sight-seeing events to make your stay enjoyable.

❖ **Credits:** SGMP, FG KMPhyto, FPH

❖ **Sponsoring:**

- Platinum (CHF 10'000+), Gold (5000+), Silver (2500+), Bronze (1000+)
- Sponsoring packages: see IMCCB-25 website
- Sponsors: tba

**For more information see IMCCB-25 website: [www.imccb.org](http://www.imccb.org)**

**For questions please contact: [info@imccb.org](mailto:info@imccb.org)**

